Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in
hair loss, that affects up to 2% of the general population. The exact pathobiology of AA has …

Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …

Importance Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an
unmet need for treatments that provide rapid and high levels of skin clearance and itch …

Background Phase 3 trials have assessed efficacy of abrocitinib versus placebo in moderate-
to-severe atopic dermatitis, a common immunoinflammatory skin disease. This study …

Owing to the limitations of the present efforts on drug discovery against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of the understanding of the …

Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population
worldwide. The characteristic white patches result from the selective loss of melanocytes …

Background Pivotal phase III studies demonstrated that abrocitinib, an oral, once-daily, JAK1-
selective inhibitor, is effective treatment for moderate-to-severe atopic dermatitis (AD) as …

Background Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory
potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy …

Background Abrocitinib efficacy by prior dupilumab response status in patients with
moderate-to-severe atopic dermatitis has not previously been assessed in phase 3 studies …

Background Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with
slightly greater prevalence in children than adults. Various treatment modalities exist; …